Appili Therapeutics (OTCMKTS:APLIF – Get Free Report) and Aclaris Therapeutics (NASDAQ:ACRS – Get Free Report) are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their institutional ownership, profitability, dividends, valuation, earnings, risk and analyst recommendations.
Risk & Volatility
Appili Therapeutics has a beta of -0.52, suggesting that its share price is 152% less volatile than the S&P 500. Comparatively, Aclaris Therapeutics has a beta of 0.54, suggesting that its share price is 46% less volatile than the S&P 500.
Analyst Recommendations
This is a breakdown of current recommendations for Appili Therapeutics and Aclaris Therapeutics, as provided by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Appili Therapeutics | 0 | 0 | 0 | 0 | 0.00 |
| Aclaris Therapeutics | 0 | 0 | 6 | 1 | 3.14 |
Valuation & Earnings
This table compares Appili Therapeutics and Aclaris Therapeutics”s top-line revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Appili Therapeutics | $630,000.00 | 4.92 | -$2.80 million | ($0.02) | -1.28 |
| Aclaris Therapeutics | $31.25 million | 5.87 | -$88.48 million | ($0.52) | -4.94 |
Appili Therapeutics has higher earnings, but lower revenue than Aclaris Therapeutics. Aclaris Therapeutics is trading at a lower price-to-earnings ratio than Appili Therapeutics, indicating that it is currently the more affordable of the two stocks.
Profitability
This table compares Appili Therapeutics and Aclaris Therapeutics’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Appili Therapeutics | N/A | N/A | -187.38% |
| Aclaris Therapeutics | -136.65% | -40.26% | -31.71% |
Insider and Institutional Ownership
98.3% of Aclaris Therapeutics shares are owned by institutional investors. 11.8% of Appili Therapeutics shares are owned by insiders. Comparatively, 6.4% of Aclaris Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.
Summary
Aclaris Therapeutics beats Appili Therapeutics on 9 of the 15 factors compared between the two stocks.
About Appili Therapeutics
Appili Therapeutics Inc., a biopharmaceutical company, focuses on the acquisition and development of novel medicines for unmet needs in infectious disease in Canada. Its anti-infective portfolio includes ATI-1501, a taste-masked liquid oral suspension formulation of the antibiotic metronidazole to treat anaerobic bacterial, protozoal, and parasitic infections; ATI-1801, a novel topical formulation of paromomycin in Phase III clinical trials for the treatment of cutaneous leishmaniasis and disfiguring skin infections; and ATI-1701, which is a live-attenuated vaccine in preclinical trials for Francisella tularensis. The company was incorporated in 2015 and is headquartered in Halifax, Canada.
About Aclaris Therapeutics
Aclaris Therapeutics, Inc. a clinical-stage biopharmaceutical company, engages in the development of novel drug candidates for immune-inflammatory diseases in the United States. The company operates through two segments, Therapeutics and Contract Research. The Therapeutics segment is involved in identifying and developing therapies to address significant unmet needs for immuno-inflammatory diseases. The Contract Research segment provides laboratory services. It develops Zunsemetinib (ATI-450), an MK2 inhibitor which is under Phase 1b/2 trials for the treatment of metastatic breast and pancreatic cancer; ATI-1777, a soft JAK 1/3 inhibitor, completed Phase 2b trails for the treatment of moderate to severe atopic dermatitis and other dermatologic conditions; and ATI-2138, an oral covalent inhibitor of ITK and JAK3 inhibitor under Phase 1 trials as a treatment for T cell-mediated autoimmune diseases. The company was incorporated in 2012 and is headquartered in Wayne, Pennsylvania.
Receive News & Ratings for Appili Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Appili Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
